Next-Generation Hardware and Wireless Communications Body Camera Solution to Law Enforcement and Other Security Markets.
NEW YORK, Apr. 30, 2015 /PRNewswire/ --DirectView Holdings, Inc. (OTC:DIRV) ("DirectView" or the "Company"), a company focused on ownership and management of leading video and security technology companies, announced its agreement with xG Technology, Inc. ("xG") (Nasdaq: XGTI, XGTIW), a developer of wireless communications and spectrum sharing technologies, to integrate DirectView's body-worn camera with xG's xMax private mobile broadband technology.
The proprietary integrated solution (code named the "DVXG-1000") is scheduled to be launched in the third quarter of 2015. The DVXG-1000 will consolidate the advanced features and functionality of DirectView's body-worn camera with the private, secure, high-performance communications capabilities of xG's xMax. Both companies intend to initially focus joint marketing efforts toward the law enforcement, military, government, education and real estate security markets. The DVXG-1000 will have a number of state of the art features including high capacity streaming video, Bluetooth®, GPS, push to talk, WIFI/4G LTE, and imbedded biometric access.
once it gets a new letter hjoe (e) it seldom gets removed. Won't believe anything company says until it is gone. Will be selling tomorrow if a (e) is still on ticker.
The lead drug in phase III has a safety profile that is superior to anything else in development for treatment up to 6 Million diabetes-related kidney disease. Company owns 100% of rights. Maybe a partnership? Might hear some news tomorrow at investor healthcare conf.
You may be right. The chart shows a breakout coming. Closed above resistance today. Investor conf. this week and 15.00 target. The lead drug in phase III has a safety profile that is superior to anything else in development for treatment up to 6 Million diabetes-related kidney disease. Company owns 100% of rights. Maybe a partnership? Might hear some news at conf.
The chart does seem to show a breakout coming. Closed above resistance today. Investor conf. wednesday. 15.00 target and lead drug phase III with safety profile that could treat up to 6 Million diabetes-related kidney disease and company owns 100% of rights. Hope to hear something Wed at the health care conf.
Many big pharma pipelines are slim these days and they are looking for this type of situation. Did more dd and think we see a buyout in next 45 days.
unexpected good news on Phase III coming. Survival extending longer than expected. Someone still may be courting CYCC for a buyout, but either way goes above 5 this week.